scholarly journals Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation

2014 ◽  
Vol 20 (7) ◽  
pp. 1033-1039 ◽  
Author(s):  
Nirali N. Shah ◽  
Michael J. Borowitz ◽  
Seth M. Steinberg ◽  
Nancy C. Robey ◽  
Christopher J. Gamper ◽  
...  
2015 ◽  
Vol 95 (2) ◽  
pp. 295-300 ◽  
Author(s):  
Jinichi Mori ◽  
Ken Ishiyama ◽  
Takuhiro Yamaguchi ◽  
Junji Tanaka ◽  
Naoyuki Uchida ◽  
...  

Blood ◽  
2020 ◽  
Vol 135 (19) ◽  
pp. 1639-1649 ◽  
Author(s):  
Alexandros Spyridonidis

Abstract Although allogeneic hematopoietic cell transplantation (allo-HCT) is currently the standard curative treatment of acute leukemia, relapse remains unacceptably high. Measurable (minimal) residual disease (MRD) after allo-HCT may be used as a predictor of impending relapse and should be part of routine follow-up for transplanted patients. Patients with MRD may respond to therapies aiming to unleash or enhance the graft-versus-leukemia effect. However, evidence-based recommendations on how to best implement MRD testing and MRD-directed therapy after allo-HCT are lacking. Here, I describe our institutional approach to MRD monitoring for preemptive MRD-triggered intervention, using patient scenarios to illustrate the discussion.


Sign in / Sign up

Export Citation Format

Share Document